Genomics has introduced the Mystra AI platform, aiming to enhance drug target discovery by leveraging extensive human genetics data.
The London-based techbio company has developed Mystra AI, a conversational AI tool designed to facilitate drug target identification and validation. This platform is already in use by prominent pharmaceutical companies and biotech startups, addressing the high failure rates in drug development, where approximately 95% of candidates fail in clinical trials. Genomics emphasizes that drug targets backed by human genetic evidence have a significantly higher success rate, being 2.6 times more likely to succeed.
Mystra AI is built upon a vast genotype-phenotype database, incorporating data from over 45,000 genome-wide association studies, which amounts to trillions of data points. This extensive dataset has enabled the identification of over 100 potential drug targets across various conditions, including cancer and diabetes. The platform features an intuitive conversational interface that allows researchers to query complex data using natural language, supported by visualizations and genetic evidence for verification.
Targeted at scientists in Research & Development as well as Business Development, Mystra AI aims to streamline the assessment of drug target efficacy and safety, explore disease mechanisms, and uncover new therapeutic avenues. The platform is being adopted by organizations like Novo Nordisk and BridgeBio Pharma, who have reported improved workflows and enhanced genomic analysis capabilities. This innovative approach could significantly accelerate the drug discovery process, making genetic insights more accessible to researchers.